Sunday, October 18, 2009

PHASE Ib CLINICAL TRIAL FOR AMD YIELDS PROMISING RESULTS.

OCT scan of a retina at 800nm with an axial re...Image via Wikipedia

MacuCLEAR, Inc. and Mystic Pharmaceuticals, Inc. have announced preliminary successful results of a Phase Ib Clinical Trial for the treatment and prevention of the progression of age-related macular degeneration (AMD). According to a press release from Mystic, the preliminary results indicated that MacuCLEAR's MC-1101 drug is safe and well tolerated by study participants, and has a biological effect on blood flow in the back of the retina. Trial participants used Mystic's VersiDoser ophthalmic delivery system to self-administer MC-1101 to the front of the eye during the trial. A key finding of the study was the successful migration of the drug to the back of the eye and the study included Proof of Concept (“POC”) indicators.


Reblog this post [with Zemanta]

0 comments:

Twitter Delicious Facebook Digg Stumbleupon Favorites More

 
Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Bluehost Review